Published in J Biol Chem on July 27, 2010
Stimulation of dendritic cells with Helicobacter pylori vacuolating cytotoxin negatively regulates their maturation via the restoration of E2F1. Clin Exp Immunol (2011) 0.89
Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma. Oncoimmunology (2015) 0.81
Identification of 14-3-3β gene as a novel miR-152 target using a proteome-based approach. J Biol Chem (2014) 0.80
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med (2014) 0.80
Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation. J Transl Med (2014) 0.78
Transcriptional activation of the human CD2AP promoter by E2F1. PLoS One (2012) 0.77
Impact of beta 2-microglobulin on tapasin expression and covalent association. Cell Immunol (2012) 0.76
E2F1: a potential therapeutic target for systematic lupus erythematosus. Rheumatol Int (2013) 0.76
Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization. Oncotarget (2016) 0.75
Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid. Oncoimmunology (2016) 0.75
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res (1983) 124.30
A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. Science (2002) 7.33
Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev (2000) 6.07
The E2F transcriptional network: old acquaintances with new faces. Oncogene (2005) 4.87
Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev (1993) 4.14
E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature (2008) 3.24
Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature (1998) 3.22
Identification of human cancers deficient in antigen processing. J Exp Med (1993) 3.21
E2Fs link the control of G1/S and G2/M transcription. EMBO J (2004) 2.81
Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today (1995) 2.74
Binding to DNA and the retinoblastoma gene product promoted by complex formation of different E2F family members. Science (1993) 2.70
Functional synergy between DP-1 and E2F-1 in the cell cycle-regulating transcription factor DRTF1/E2F. EMBO J (1993) 2.55
The multi-tasking P-TEFb complex. Curr Opin Cell Biol (2008) 2.53
MHC class I antigen presentation: learning from viral evasion strategies. Nat Rev Immunol (2009) 2.49
Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J (2002) 2.49
A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science (1997) 2.18
E2F in vivo binding specificity: comparison of consensus versus nonconsensus binding sites. Genome Res (2008) 2.07
E2F-associated chromatin modifiers and cell cycle control. Curr Opin Cell Biol (2007) 2.04
E2F-dependent histone acetylation and recruitment of the Tip60 acetyltransferase complex to chromatin in late G1. Mol Cell Biol (2004) 1.85
Antigen-processing machinery breakdown and tumor growth. Immunol Today (2000) 1.82
Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor. Mol Cell Biol (2003) 1.76
Recent advances in antigen processing and presentation. Nat Immunol (2007) 1.75
The identification of E2F1-specific target genes. Proc Natl Acad Sci U S A (2002) 1.63
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene (2008) 1.59
Transcriptional control by E2F. Semin Cancer Biol (1995) 1.58
Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter. J Exp Med (1995) 1.46
Impaired immune responses and altered peptide repertoire in tapasin-deficient mice. Nat Immunol (2000) 1.44
TAP off--tumors on. Immunol Today (1997) 1.43
Transcriptional regulation. A closer look at E2F. Nature (1992) 1.39
Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother (2007) 1.38
Transcriptional regulation of antigen presentation. Curr Opin Immunol (2004) 1.34
Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. J Immunol (1999) 1.33
Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res (2005) 1.32
Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother (2008) 1.31
MHC class I assembly: out and about. Trends Immunol (2008) 1.29
HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res (2004) 1.26
Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res (2001) 1.25
Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res (2008) 1.24
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer (2004) 1.17
Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene (2005) 1.13
Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma. Genes Chromosomes Cancer (2009) 1.12
Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens (2003) 1.09
Shared regulatory elements in the promoters of MHC class I and class II genes. Immunol Today (1998) 1.08
The spanish connection: transcription and mRNA processing get even closer. Cell (2005) 1.08
Kinetically coordinated induction of TAP1 and HLA class I by IFN-gamma: the rapid induction of TAP1 by IFN-gamma is mediated by Stat1 alpha. J Immunol (1996) 1.07
An improved method for Southwestern blotting. Front Biosci (1997) 1.04
Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. Cancer Res (2000) 1.04
Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element. J Immunol (1999) 1.03
Cytokines increase transporter in antigen processing-1 expression more rapidly than HLA class I expression in endothelial cells. J Immunol (1992) 1.02
MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer (2004) 1.01
Regulation of murine Tap1 and Lmp2 genes in macrophages by interferon gamma is mediated by STAT1 and IRF-1. Genes Immun (2004) 1.00
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother (2008) 1.00
Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res (2005) 0.98
Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta (2007) 0.97
IFN regulatory factor-2 cooperates with STAT1 to regulate transporter associated with antigen processing-1 promoter activity. J Immunol (2005) 0.97
A combinatorial mechanism for determining the specificity of E2F activation and repression. Oncogene (2009) 0.94
Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. Int J Cancer (2009) 0.93
PRDM1/BLIMP-1 modulates IFN-gamma-dependent control of the MHC class I antigen-processing and peptide-loading pathway. J Immunol (2007) 0.93
Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem (2006) 0.93
Epigenetic control of the immune escape mechanisms in malignant carcinomas. Mol Cell Biol (2007) 0.92
Genomic analysis of the Tapasin gene, located close to the TAP loci in the MHC. Eur J Immunol (1998) 0.91
Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother (2008) 0.91
Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer (2005) 0.91
MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer (2003) 0.90
Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother (2002) 0.90
Regulation of the expression of mouse TAP-associated glycoprotein (tapasin) by cytokines. Immunol Lett (2002) 0.90
Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin. Bone Marrow Transplant (2000) 0.89
MHC class I gene expression and regulation. J Hematother Stem Cell Res (2000) 0.89
The PML gene is not involved in the regulation of MHC class I expression in human cell lines. Blood (2002) 0.88
CD40 induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF-kappaB and of NF-kappaB-mediated de novo synthesis of IRF-1. Mol Cell Biol (2008) 0.87
Cloning and functional analyses of the mouse tapasin promoter. Immunogenetics (2003) 0.87
LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J Exp Med (1996) 0.86
Downregulation of tapasin expression in progressive human malignant melanoma. Arch Dermatol Res (2003) 0.86
Accessory molecules in the assembly of major histocompatibility complex class I/peptide complexes: how essential are they for CD8(+) T-cell immune responses? Immunol Rev (2005) 0.86
Differential expression of tapasin and immunoproteasome subunits in adenovirus type 5- versus type 12-transformed cells. J Biol Chem (2002) 0.84
Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. Tissue Antigens (2001) 0.83
Gene transfer of the Co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent. Scand J Immunol (1999) 0.83
Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. Cancer Immunol Immunother (2009) 0.83
Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16. Br J Cancer (2001) 0.82
The transcription elongation factors NELF, DSIF and P-TEFb control constitutive transcription in a gene-specific manner. FEBS Lett (2009) 0.82
Antigen processing and presentation by human trophoblast-derived cell lines. J Immunol (1997) 0.82
Organization and functional analysis of the mouse transporter associated with antigen processing 2 promoter. J Immunol (2001) 0.82
Ectopic expression of pRb2/p130 suppresses the tumorigenicity of the c-erbB-2-overexpressing SKOV3 tumor cell line. Oncogene (1999) 0.82
Repression of the minimal HLA-B promoter by c-myc and p53 occurs through independent mechanisms. Mol Immunol (1998) 0.82
Genomic organization of the mouse Lmp-2 gene and characteristic structure of its promoter. Gene (1993) 0.81
Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer. Tissue Antigens (2009) 0.80
Involvement of the chaperone tapasin in HLA-B44 allelic losses in colorectal tumors. Int J Cancer (2005) 0.77
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res (2005) 1.68
Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67
A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res (2003) 1.63
Common cancer biomarkers. Cancer Res (2006) 1.56
Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation. Transplantation (2012) 1.52
The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med (2011) 1.47
Altered detoxification status and increased resistance to oxidative stress by K-ras transformation. Cancer Res (2008) 1.39
5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res (2002) 1.27
HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res (2004) 1.26
Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol (2003) 1.23
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A (2008) 1.18
B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin Cancer Res (2011) 1.17
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer (2004) 1.17
The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol (2012) 1.12
Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol (2004) 1.10
Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother (2009) 1.08
Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin Cancer Res (2011) 1.04
T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer (2010) 1.03
Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res (2003) 1.03
Melanoma-restricted genes. J Transl Med (2004) 1.03
MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer (2004) 1.01
HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. J Immunol (2012) 1.00
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother (2008) 1.00
Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma. Cancer Immunol Immunother (2010) 1.00
Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cell Mol Life Sci (2010) 0.98
Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res (2005) 0.98
Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer Res (2006) 0.97
Identification and validation of novel ERBB2 (HER2, NEU) targets including genes involved in angiogenesis. Int J Cancer (2005) 0.97
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol (2013) 0.96
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med (2013) 0.95
Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics (2002) 0.94
Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor. Int J Cancer (2011) 0.94
Methylation-specific ligation detection reaction (msLDR): a new approach for multiplex evaluation of methylation patterns. Mol Genet Genomics (2011) 0.93
Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. Cancer Res (2003) 0.93
Tuning tumor-specific T-cell activation: a matter of costimulation? Trends Immunol (2002) 0.92
Systematic comparative protein expression profiling of clear cell renal cell carcinoma: a pilot study based on the separation of tissue specimens by two-dimensional gel electrophoresis. Mol Cell Proteomics (2009) 0.92
Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma. Proteomics (2002) 0.91
High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res (2004) 0.91
Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clin Immunol (2011) 0.91
Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma. J Transl Med (2009) 0.91
CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer (2004) 0.90
Monitoring peri-operative immune suppression in renal cancer patients. Oncol Rep (2011) 0.90
Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues. Int J Cancer (2007) 0.89
Heat shock proteins in renal cell carcinomas. Contrib Nephrol (2005) 0.88
Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta (2003) 0.88
Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. Cancer Res (2004) 0.87
Cloning and functional analyses of the mouse tapasin promoter. Immunogenetics (2003) 0.87
Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J Biol Chem (2013) 0.86
Comparative expression profiling of distinct T cell subsets undergoing oxidative stress. PLoS One (2012) 0.85
Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. Hum Immunol (2003) 0.85
Fast dendritic cells stimulated with alternative maturation mixtures induce polyfunctional and long-lasting activation of innate and adaptive effector cells with tumor-killing capabilities. J Immunol (2013) 0.84
Influence of Ki-ras-driven oncogenic transformation on the protein network of murine fibroblasts. Proteomics (2007) 0.84
HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties. J Biol Chem (2012) 0.84
Functional cysteine-less subunits of the transporter associated with antigen processing (TAP1 and TAP2) by de novo gene assembly. FEBS Lett (2003) 0.84
Aminopeptidase N (APN)/CD13-dependent CXCR4 downregulation is associated with diminished cell migration, proliferation and invasion. Mol Membr Biol (2008) 0.83
B7/CD28 costimulation of T cells induces a distinct proteome pattern. Mol Cell Proteomics (2005) 0.82
Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother (2012) 0.82
Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides. Int J Cancer (2002) 0.82
HLA-dependent tumour development: a role for tumour associate macrophages? J Transl Med (2013) 0.82
Regulation of beta1 integrin expression by PKCepsilon in renal cancer cells. Int J Oncol (2004) 0.81
CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells. Arch Dermatol Res (2008) 0.81
Impaired transporter associated with antigen processing (TAP) function attributable to a single amino acid alteration in the peptide TAP subunit TAP1. J Immunol (2003) 0.80
HER-2/neu mediates oncogenic transformation via altered CREB expression and function. Mol Cancer Res (2013) 0.80
A proteomic view at T cell costimulation. PLoS One (2012) 0.80
The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma. Cancer Immunol Immunother (2009) 0.80
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system. Proteomics (2010) 0.80
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med (2014) 0.80
Sub-bandgap absorption in organic solar cells: experiment and theory. Phys Chem Chem Phys (2013) 0.79
Predominance of TH2 cells and plasma cells in polyoma virus nephropathy: a role for humoral immunity? Hum Pathol (2012) 0.79
The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases. Histopathology (2013) 0.79
Comparative expression profiling for human endoplasmic reticulum-resident aminopeptidases 1 and 2 in normal kidney versus distinct renal cell carcinoma subtypes. Int J Clin Exp Pathol (2013) 0.79
Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors. Cancer Res (2002) 0.78
Promoter methylation of aminopeptidase N/CD13 in malignant melanoma. Carcinogenesis (2012) 0.78
The non-classical antigens of HLA-G and HLA-E as diagnostic and prognostic biomarkers and as therapeutic targets in transplantation and tumors. Clin Transpl (2013) 0.78
Predictive immunomonitoring -- the COST ENTIRE initiative. Clin Immunol (2013) 0.78
Analysis of the structural integrity of the TAP2 gene in renal cell carcinoma. Int J Oncol (2003) 0.78
The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies. Semin Cancer Biol (2003) 0.78
High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection? Nephrol Dial Transplant (2007) 0.78
Heterogeneous expression and functional relevance of the ubiquitin carboxyl-terminal hydrolase L1 in melanoma. Int J Cancer (2013) 0.77
Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1. Vaccine (2006) 0.77
"Tumor immunology meets oncology IV", 23rd and 24th May 2008 Martin Luther University Halle-Wittenberg, Halle, Germany. Cancer Immunol Immunother (2008) 0.77
Opposing consequences of signaling through EGF family members: Escape from CTLs could be a bait for NK cells. Oncoimmunology (2012) 0.77
B7-1 and B7-2 act differentially in the induction of a T cell response: their impact for a HLA-matched and HLA-mismatched anti-tumor immunotherapy. Int J Cancer (2005) 0.76
"Tumor Immunology Meets Oncology (TIMO) VIII" from May 4 to 5, 2012, in Halle/Saale, Germany. Cancer Immunol Immunother (2012) 0.75
"Tumor immunology meets oncology (TIMO) VI" from 7th to 8th of May 2010 in Halle, Germany. Cancer Immunol Immunother (2010) 0.75
Correction: Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion. Oncotarget (2017) 0.75
"Tumor immunology meets oncology" (TIMO) X, May 23-24, 2014, Halle/Saale, Germany. Cancer Immunol Immunother (2015) 0.75
Adiponectin and Its Receptors Are Differentially Expressed in Human Tissues and Cell Lines of Distinct Origin. Obes Facts (2017) 0.75
A Wavelet Approach to Detecting Electrocautery Noise in the ECG. Conf Proc IEEE Eng Med Biol Soc (2005) 0.75
A Wavelet Approach to Detecting Electrocautery Noise in the ECG. Conf Proc IEEE Eng Med Biol Soc (2005) 0.75
Low frequency of HLA haplotype loss associated with loss of heterozygocity in chromosome region 6p21 in clear renal cell carcinomas. Int J Cancer (2004) 0.75
Impact of the mitogen-activated protein kinase pathway on the subproteome of detergent-resistant microdomains of colon carcinoma cells. Proteomics (2015) 0.75